Improving patient outcomes in an ambulatory infusion setting: Decreasing infusion reactions of patients receiving paclitaxel and carboplatin

Journal of Infusion Nursing

Volumn 28, Issue 3, 2005, Pages 170-172

  Huddleston, Roseann ^a,b   Berkheimer, Carol ^c,d   Landis, Sandra ^c,e   Houck, Dereen ^f   Proctor, Ann ^f,g   Whiteford, Joan ^c,h  

^a Oncology Service Line   (United States)

^b St Joseph's Hospital School of Nursing   (United States)

^c Apple Hill Infusion Center   (United States)

^d York College   (United States)

^e Lancaster General School of Nursing   (United States)

^f YORK HOSPITAL   (United Kingdom)

^g TOWSON UNIVERSITY   (United States)

^h READING HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ALLERGIC REACTION; AMBULATORY CARE; BACKACHE; DIZZINESS; DRUG DOSE REGIMEN; FLUSHING; HUMAN; HYPERTENSION; HYPOTENSION; INFUSION; NAUSEA; NURSE; NURSING; OUTPATIENT CARE; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME;

EID: 18444386233     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200505000-00004     Document Type: Review

References (9)

1. Cella D, Peterman A, Hudgens S, Webster K, Socinski M. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane. Cancer. 2003;98(4):822-831.
2. Myers J. Hypersensitivity reaction to paclitaxel: nursing interventions clinical. Clin J Oncol Nurs. 2000;4(4):161-163.
3. Myers J. Paclitaxel-related hypersensitivity reactions and monitoring recommendations. Clin Oncol Nurs. 2002;6(3):177-178.
4. Markham M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18(1):102-105.
5. Price K, Castells M. Taxol reactions. Allergy Asthma Proc. 2002;23(3):205-208.
6. Markham M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17(4):1141.
7. Cormio G, Divango G, Melilli GA, et al. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemother. 1999;11(5):407-409.
8. Kintzel P. Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother.2001;35(9):1114-1117.
9. Kloover J, Den Bakker M, Gelderblom H, Van Meerbeck J. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer. 2004;90(2):304-305.